Related Experiment Video

Updated: Jun 22, 2026

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

Defining success in clinical trials of diabetic foot wounds: the Los Angeles DFCon consensus

David G Armstrong1, Andrew J M Boulton, George Andros

  • 1Southern Arizona Limb Salvage Alliance, University of Arizona College of Medicine, Tucson, 85701, AZ, USA. armstrong@usa.net

International Wound Journal
|June 23, 2009
PubMed

Insights

Developing better clinical trial endpoints for wound healing products is crucial. This will ensure patient safety and product efficacy while streamlining the regulatory process for diabetic foot ulcer treatments.

Area of Science:

  • Wound healing research
  • Biomedical engineering
  • Regulatory science

Background:

  • Diabetic foot ulcers present complex healing challenges, often requiring multifaceted treatment approaches.
  • Current regulatory guidance for wound care products, established in 2006, needs updating to reflect advancements in wound healing science.
  • Existing clinical trial endpoints may not adequately capture the efficacy of novel wound management modalities.

Purpose of the Study:

  • To propose improved, meaningful study outcomes and endpoints for wound care clinical trials.
  • To facilitate the development and approval process for new wound healing products.
  • To establish consensus on primary outcomes and secondary endpoints for various wound healing modalities.

Main Methods:

  • Convened an interdisciplinary task force of wound care experts.
  • Reviewed existing regulatory guidance from the US Food and Drug Administration (FDA).
  • Focused on achieving consensus for defining primary outcomes and secondary endpoints.

Main Results:

  • Identified the need for more effective clinical trial endpoints in wound healing.
  • Highlighted the complexity of wound healing, suggesting single-compound efficacy is unlikely.
  • Initiated a process to redefine primary outcomes and secondary endpoints for wound care trials.

Conclusions:

  • Revised clinical trial endpoints are essential for accurately assessing wound management efficacy.
  • Updated guidance will support the development of safe and effective wound healing products.
  • Consensus-driven endpoint definition will improve regulatory pathways and patient care for diabetic foot ulcers.

Related Concept Videos

Diabetic Foot Ulcer01:31

Diabetic Foot Ulcer

Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...